Peroxisome proliferator-activated receptor γ gene polymorphism is associated with serum triglyceride levels and body mass index in Japanese type 2 diabetic patients

Journal of Clinical Laboratory Analysis

Volumn 18, Issue 6, 2004, Pages 317-321

  Maeda, Atsuko ^a   Gohda, Tomohito ^a   Funabiki, Kazuhiko ^a   Horikoshi, Satoshi ^a   Tomino, Yasuhiko ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

BMI; Diabetes; Polymorphism; PPAR

Indexed keywords

HEMOGLOBIN A1C; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRIACYLGLYCEROL;

ADULT; AGED; ALLELE; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; EXON; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; INSULIN RESISTANCE; JAPAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; FEMALE; GENE FREQUENCY; HUMANS; INSULIN RESISTANCE; JAPAN; MALE; MIDDLE AGED; OBESITY; POLYMORPHISM, GENETIC; PPAR GAMMA; TRIGLYCERIDES;

EID: 9644281552     PISSN: 08878013     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcla.20045     Document Type: Article

References (17)

1. Krolewski AS, Warram JH, Rand LI, Kahn CR. 1987. Epidemiologic approach to the etiology of type I diabetes mellitus and its complications. N Engl J Med 317:1390-1398.
2. Seaquist ER, Goetz FC, Rich S, Barbosa J. 1989. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 320:1161-1165.
3. Quinn M, Angelico MC, Warram JH, Krolewski AS. 1996. Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia 39:940-945.
4. Pettitt DJ, Saad MF, Bennett PH, Nelson RG, Knowler WC. 1990. Familial predisposition to renal disease in two generations of Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 33:438-443.
5. Brun RP, Tontonoz P, Forman BM, et al. 1996. Differential activation of adipogenesis by multiple PPAR isoforms. Genes Dev 10:974-984.
6. Fajas L, Auboeuf D, Raspe E, et al. 1997. The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 272:18779-18789.
7. Fajas L, Fruchart JC, Auwerx J. 1998. PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promoter. FEBS Lett 438:55-60.
8. Ricote M, Huang J, Fajas L, et al. 1998. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA 95:7614-7619.
9. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. 1995. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270:12953-12956.
10. Antonucci T, Whitcomb R, McLain R, Lockwood D, Norris RM. 1997. Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone. Diabetes Care 20:188-193.
11. Meirhaeghe A, Fajas L, Helbecque N, et al. 1998. A genetic polymorphism of the peroxisome proliferator-activated receptor gamma gene influences plasma leptin levels in obese humans. Hum Mol Genet 7:435-440.
12. Mori H, Ikegami H, Kawaguchi Y, et al. 2001. The Pro12 -> Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes 50:891-894.
13. Altshuler D, Hirschhorn JN, Klannemark M, et al. 2000. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26:76-80.
14. Oh EY, Min KM, Chung JH, et al. 2000. Significance of Pro12Ala mutation in peroxisome proliferator-activated receptor-gamma2 in Korean diabetic and obese subjects. J Clin Endocrinol Metab 85:1801-1804.
15. Mancini FP, Vaccaro O, Sabatino L, et al. 1999. Pro12Ala substitution in the peroxisome proliferator-activated receptor-gamma2 is not associated with type 2 diabetes. Diabetes 48:1466-1468.
16. Kubota N, Terauchi Y, Miki H, et al. 1999. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 4:597-609.
17. Werman A, Hollenberg A, Solanes G, Bjorbaek C, Vidal-Puig AJ, Flier JS. 1997. Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma). Differential activity of PPARgamma 1 and -2 isoforms and influence of insulin. J Biol Chem 272:20230-20235.